Abstract
Alzheimer’s disease (AD) is a progressive neurodegenerative disease that is the most common cause of dementia. Symptoms of AD include memory loss, disorientation, mood and behavior changes, confusion, unfounded suspicions, and eventually, difficulty speaking, swallowing, and walking. These symptoms are caused by neuronal degeneration and cell loss that begins in the hippocampus, and later in disease progression spreading to the rest of the brain. While there are some medications that alleviate initial symptoms, there are currently no treatments that stop disease progression. Hippocampal deficits in amyloid-β-related rodent models of AD have revealed synaptic, behavioral and circuit-level defects. These changes in synaptic function, plasticity, neuronal excitability, brain connectivity, and excitation/inhibition imbalance all have profound effects on circuit function, which in turn could exacerbate disease progression. Despite, the wealth of studies on AD pathology we don’t yet have a complete understanding of hippocampal deficits in AD. With the increasing development of in vivo recording techniques in awake and freely moving animals, future studies will extend our current knowledge of the mechanisms underpinning how hippocampal function is altered in AD, and aid in progression of treatment strategies that prevent and/or delay AD symptoms.
Highlights
Alzheimer’s disease (AD) is the most common neurodegenerative disease affecting more than 40 million people worldwide (Alzheimer’s Disease International, 2018)
The hippocampus is widely studied in AD as this brain region is essential for forming new memories, and the progressive degeneration of neurons in the hippocampus responsible for short-term memory loss is a hallmark effect of AD (West et al, 1994, 2004; Fox et al, 1996)
Microscopic changes in the hippocampus precede behavioral symptomology in AD patients and mouse models; this review will focus on hippocampal deficits observed in AD
Summary
Alzheimer’s disease (AD) is the most common neurodegenerative disease affecting more than 40 million people worldwide (Alzheimer’s Disease International, 2018). Additional models include transgenic mice expressing the human APP (hAPP), as well as the SAMP8 mouse model that spontaneously develops AD (Mucke et al, 1996; Morley et al, 2000). Each of these models displays some deficits associated with AD, the difficulty has been generating models where disease progression reaches stage 3 within the shorter lifespan of rodents. Seizures worsen disease progression (Volicer et al, 1995) whereas anti-epileptic drugs improve memory impairments in individuals with mild cognitive impairment (Bakker et al, 2015)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.